References
- Poon MC, Di Minno G, Zotz R, et al. Glanzmann’s thrombasthenia: strategies for identification and management. Expert Opin Orphan Drugs. 2017;5(8):641–653.
- Ghosh K, Shetty S. Glanzmann’s thrombasthenia – newer treatment options. Expert Opin Orphan Drugs. 2014;2:5–10.
- Greinacher A, Pecci A, Kunishima S, et al. Diagnosis of inherited platelet disorders on a blood smear: a tool to facilitate worldwide diagnosis of platelet disorders. J Thromb Haemost. 2017;15:1511–1521.
- Nair S, Ghosh K, Kulkarni B, et al. Glanzmann’s thrombasthenia: updated. Platelets. 2002;13:387–393.
- Nurden AT, Fiore M, Nurden P et al. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood. 2011;118:5996–6005.
- Plow EF, Qin J, Byzova T. Kindling the flame of integrin activation and function with kindlins. Curr Opin Hematol. 2009;16:323–328.
- Ali S, Ghosh K, Daly ME, et al. Congenital macrothrombocytopenia is a heterogeneous disorder in India. Haemophilia. 2016;22:570–582.
- Vijapurkar M, Ghosh K, Shetty S, et al. A simple, novel and robust test to diagnose type I Glanzmann thrombasthenia. Haematologica. 2008;93:797–798.
- Kulkarni BP, Nair SB, Vijapurkar M, et al. Molecular pathology of rare bleeding disorders (RBDs) in India: a systematic review. PLoS One. 2014;9(9):e108683.
- Hacıoğlu SK, Doğu MH, Sarı İ, et al. Successful treatment of refractory gastrointestinal bleeding by systemic (oral)ankaferd blood stopper in a patient with Glanzmann thrombasthenia. Balkan Med J. 2015;32:218–220.
- Fogarty PF. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology Am Soc Hematol Educ Program. 2011;2011:397–404.
- Parng C, Markiewicz V, Chen J, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and interspecies scaling of recombinant human coagulation factor XaI16L. J Pharm Sci. 2017;106:2136–2143.
- Smith SA, Morrissey JH. Polyphosphate as a general procoagulant agent. J Thromb Haemost. 2008;6:1750–1756.
- Blajchman MA. Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost. 2003;1:1637–1641.
- Wilcox DA, Olsen JC, Ishizawa L, et al. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood. 2000;95:3645–3651.
- Roy B, Friesen WJ, Tomizawa Y, et al. Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci U S A. 2016;113:12508–12513.
- Yang F, Wen W, Qin W. Bispecific antibodies as a development platform for new concepts and treatment strategies. Int J Mol Sci. 2016 Dec 28;18:E48.
- Watts T, Barigou M, Nash GB. Effects of vessel size, cell sedimentation and haematocrit on the adhesion of leukocytes and platelets from flowing blood. Biorheology. 2015;52:391–404.